WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317556
CAS#: 120202-66-6 (sulfate)
Description: Clopidogrel (INN) is an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, cerebrovascular disease, and to prevent myocardial infarction (heart attack) and stroke. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Clopidogrel acts by inhibiting the ADP receptor on platelet cell membranes. It is a prodrug, which requires CYP2C19 for its activation.
MedKoo Cat#: 317556
Name: Clopidogrel sulfate
CAS#: 120202-66-6 (sulfate)
Chemical Formula: C16H18ClNO6S2
Exact Mass: 321.05903
Molecular Weight: 419.891
Elemental Analysis: C, 45.77; H, 4.32; Cl, 8.44; N, 3.34; O, 22.86; S, 15.27
Clopidogrel sulfate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Related CAS #: 120202-66-6 (bisulfate) 120202-65-5 (HCl) 90055-48-4 (racemic) 744256-69-7 (besylate) 120202-67-7 (HBr)
Synonym: Plavix; (S)-Clopidogrel; Clopidogrelum; Zyllt. Clopidogrel sulfate; Osvix; Plavitor, SR 25990C; SR-25990C; SR25990C; SR 25990.
IUPAC/Chemical Name: methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate sulfate
InChi Key: FDEODCTUSIWGLK-RSAXXLAASA-N
InChi Code: InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1
SMILES Code: O=C(OC)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C=CS3)C2.O=S(O)(O)=O
The following data is based on the product molecular weight 419.891 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Khodor S, Castro M, McNamara C, Chaulagain CP. Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. Hematol Oncol Stem Cell Ther. 2015 Dec 2. pii: S1658-3876(15)00105-3. doi: 10.1016/j.hemonc.2015.11.003. [Epub ahead of print] PubMed PMID: 26684918.
2: Zhang JR, Wang DQ, Du J, Qu GS, Du JL, Deng SB, Liu YJ, Cai JX, She Q. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore). 2015 Dec;94(50):e2262. doi: 10.1097/MD.0000000000002262. PubMed PMID: 26683949.
3: Yang YG, Zhang M, Jiang N, Song LX, Xu XT, Di XH, Xu L, Xu J, Zhao GT. Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. Genet Mol Res. 2015 Dec 14;14(4):16736-43. doi: 10.4238/2015.December14.1. PubMed PMID: 26681020.
4: Ketterer U, D Ancona G, Siegel I, Ortak J, Ince H, Kische S. Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders. Int J Cardiol. 2015 Nov 24;204:196-197. doi: 10.1016/j.ijcard.2015.11.160. [Epub ahead of print] PubMed PMID: 26670171.
5: Zhai Y, Wang L, Yang F, Feng G, Feng S, Cui T, An L, He X. The mechanism and risk factors of clopidogrel-induced liver injury. Drug Chem Toxicol. 2015 Dec 11:1-8. [Epub ahead of print] PubMed PMID: 26654298.
6: Nishimura AA, Shirts BH, Salama J, Smith JW, Devine B, Tarczy-Hornoch P. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2015 Nov 11. pii: S1386-5056(15)30056-3. doi: 10.1016/j.ijmedinf.2015.11.004. [Epub ahead of print] PubMed PMID: 26642939.
7: Dobesh PP, Varnado S, Doyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. Curr Pharm Des. 2015 Dec 8. [Epub ahead of print] PubMed PMID: 26642781.
8: Braun D, Knipper A, Orban M, Sibbing D, Petzold T, Braun S, Schulz S, Hausleiter J, Kastrati A, Mehilli J, Massberg S. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thromb Res. 2015 Nov 19. pii: S0049-3848(15)30192-4. doi: 10.1016/j.thromres.2015.11.016. [Epub ahead of print] PubMed PMID: 26639204.
9: Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2015 Dec 5. pii: ehv611. [Epub ahead of print] PubMed PMID: 26637834.
10: Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni M, Guzman LA, Bass TA, Ajjan RA, Angiolillo DJ. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost. 2015 Dec 3;115(3). [Epub ahead of print] PubMed PMID: 26633836.
